New Synapse product enhancements streamline workflows and patient engagement capabilities for radiologists and radiology imaging centers
Lexington, Mass., November 23, 2021 – FUJIFILM Healthcare Americas Corporation announced it will showcase advancements to its Synapse Enterprise Imaging portfolio at the 2021 Radiological Society of North America (RSNA) conference, booth #1911, from November 28 – December 2, 2021 at McCormick Place West in Chicago.
New to the Fujifilm booth this year among many other highlights, Synapse 7x clients leverage our decades of PACS experience in radiology to cardiology that expand into enhanced cardiology reporting capabilities; Synapse 3D advanced visualization native to radiology and cardiology PACS workflows; Synapse VNA showcases point-of-care workflow solutions across enterprise, and Synapse Enterprise Information System (EIS) clients and their patients will experience improved patient engagement capabilities for scheduling, document/information sharing, patient/provider communications and more.
“We continue to advance our Synapse Enterprise Imaging portfolio to unify imaging and expand data access across the entire healthcare enterprise,’ said Bill Lacy, senior vice president, medical informatics, FUJIFILM Healthcare Americas Corporation” At RSNA 2021, we’re excited to unveil a number of Synapse software enhancements that drive cross-departmental collaboration, workflow efficiency and more-informed clinical decision making.”
At RSNA 2021, Fujifilm will showcase:
To learn more about Fujifilm’s presence at RSNA 2021 and to schedule an on-site meeting, please visit: rsna.fujimed.com
FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image -processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information please visit healthcaresolutions-us.fujifilm.com.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com